Skalis Georgios, Katsi Vasiliki, Miliou Antigoni, Georgiopoulos Georgios, Papazachou Ourania, Vamvakou Georgia, Nihoyannopoulos Petros, Tousoulis Dimitrios, Makris Thomas
Department of Cardiology, Helena Venizelou Hospital, Athens, Greece.
Cardiology Department, Hippokration Hospital, National Health System, Athens, Greece.
Microrna. 2019;8(1):28-35. doi: 10.2174/2211536607666180813123303.
Preeclampsia (PE) continues to represent a worldwide problem and challenge for both clinicians and laboratory-based doctors. Despite many efforts, the knowledge acquired regarding its pathogenesis and pathophysiology does not allow us to treat it efficiently. It is not possible to arrest its progressive nature, and the available therapies are limited to symptomatic treatment. Furthermore, both the diagnosis and prognosis are frequently uncertain, whilst the ability to predict its occurrence is very limited. MicroRNAs are small non-coding RNAs discovered two decades ago, and present great interest given their ability to regulate almost every aspect of the cell function. A lot of evidence regarding the role of miRNAs in pre-eclampsia has been accumulated in the last 10 years. Differentially expressed miRNAs are characteristic of both mild and severe PE. In many cases they target signaling pathway-related genes that result in altered processes which are directly involved in PE. Immune system, angiogenesis and trophoblast proliferation and invasion, all fundamental aspects of placentation, are controlled in various degrees by miRNAs which are up- or downregulated. Finally, miRNAs represent a potential therapeutic target and a diagnostic tool.
子痫前期(PE)仍然是一个全球性问题,对临床医生和实验室医生来说都是挑战。尽管付出了诸多努力,但就其发病机制和病理生理学所获得的知识仍无法让我们有效地治疗它。无法阻止其进展性,现有的治疗方法仅限于对症治疗。此外,诊断和预后常常不确定,而预测其发生的能力非常有限。微小RNA是二十年前发现的小型非编码RNA,鉴于它们能够调节细胞功能的几乎每个方面,因此备受关注。在过去十年中,已经积累了大量关于微小RNA在子痫前期中作用的证据。差异表达的微小RNA是轻度和重度子痫前期的特征。在许多情况下,它们靶向与信号通路相关的基因,这些基因导致直接参与子痫前期的过程发生改变。免疫系统、血管生成以及滋养层细胞的增殖和侵袭,这些胎盘形成的所有基本方面,都受到上调或下调的微小RNA不同程度的控制。最后,微小RNA代表了一个潜在的治疗靶点和诊断工具。